Levels of miR-29b do not predict for response in patients with acute myelogenous leukemia treated with the combination of 5-azacytidine, valproic acid, and ATRA.

Andres O. Soriano, Hui Yang, Stefan Faderl, Zeev Estrov, Francis Giles, Farhad Ravandi, Jorge Cortes, William G. Wierda, Souzanne Ouzounian, Andres Quezada, Sherry Pierce, Elihu H. Estey, Jean-Pierre J. Issa, Hagop M. Kantarjian, Guillermo Garcia-Manero, Safety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome Blood. ,vol. 110, pp. 2302- 2308 ,(2007) , 10.1182/BLOOD-2007-03-078576

Ramiro Garzon, Shujun Liu, Muller Fabbri, Zhongfa Liu, Catherine EA Heaphy, Elisa Callegari, Sebastian Schwind, Jiuxia Pang, Jianhua Yu, Natarajan Muthusamy, Violaine Havelange, Stefano Volinia, William Blum, Laura J Rush, Danilo Perrotti, Michael Andreeff, Clara D Bloomfield, John C Byrd, Kenneth Chan, Lai-Chu Wu, Carlo M Croce, Guido Marcucci, None, MicroRNA-29b induces global DNA hypomethylation and tumor suppressor gene reexpression in acute myeloid leukemia by targeting directly DNMT3A and 3B and indirectly DNMT1. Blood. ,vol. 113, pp. 6411- 6418 ,(2009) , 10.1182/BLOOD-2008-07-170589

Ramiro Garzon, Stefano Volinia, Chang-Gong Liu, Cecilia Fernandez-Cymering, Tiziana Palumbo, Flavia Pichiorri, Muller Fabbri, Kevin Coombes, Hansjuerg Alder, Tatsuya Nakamura, Neal Flomenberg, Guido Marcucci, George A. Calin, Steven M. Kornblau, Hagop Kantarjian, Clara D. Bloomfield, Michael Andreeff, Carlo M. Croce, MicroRNA signatures associated with cytogenetics and prognosis in acute myeloid leukemia Blood. ,vol. 111, pp. 3183- 3189 ,(2008) , 10.1182/BLOOD-2007-07-098749

W. Blum, R. Garzon, R. B. Klisovic, S. Schwind, A. Walker, S. Geyer, S. Liu, V. Havelange, H. Becker, L. Schaaf, J. Mickle, H. Devine, C. Kefauver, S. M. Devine, K. K. Chan, N. A. Heerema, C. D. Bloomfield, M. R. Grever, J. C. Byrd, M. Villalona-Calero, C. M. Croce, G. Marcucci, Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine Proceedings of the National Academy of Sciences of the United States of America. ,vol. 107, pp. 7473- 7478 ,(2010) , 10.1073/PNAS.1002650107

M Fabbri, R Garzon, M Andreeff, H M Kantarjian, G Garcia-Manero, G A Calin, MicroRNAs and noncoding RNAs in hematological malignancies: molecular, clinical and therapeutic implications Leukemia. ,vol. 22, pp. 1095- 1105 ,(2008) , 10.1038/LEU.2008.30

Guillermo Garcia-Manero, Hagop M. Kantarjian, Blanca Sanchez-Gonzalez, Hui Yang, Gary Rosner, Srdan Verstovsek, Michael Rytting, William G. Wierda, Farhad Ravandi, Charles Koller, Lianchun Xiao, Stefan Faderl, Zeev Estrov, Jorge Cortes, Susan O'Brien, Elihu Estey, Carlos Bueso-Ramos, Jackie Fiorentino, Elias Jabbour, Jean-Pierre Issa, Phase 1/2 study of the combination of 5-aza-2'-deoxycytidine with valproic acid in patients with leukemia. Blood. ,vol. 108, pp. 3271- 3279 ,(2006) , 10.1182/BLOOD-2006-03-009142